Brief Description
The purpose of this study is to assess the efficacy and safety of iptacopan compared to placebo (both administered in combination with stand of care) in patients with idiopathic IC-MPGN. This study will look at the effects of iptacopan on the level of protein in the urine and kidney function.
Estimated Enrollment
1
Estimated End Date
Jul-27
Trial is for people with
Trial is for people between 12 and 60 years old and have been diagnosed with idiopathic IC-MPGN. Other tests will be done during the ...
Study Goal
The APPARENT study seeks to find out if iptacopan is effective and safe as compared to placebo in people who have been diagnosed with ...
What is involved for the patient?
If you take part in the study you will be given iptacopan or placebo. Participants will take either iptacopan or placebo for the first ...
About the drug or intervention
Iptacopan is an investigational drug Novartis is studying as a potential targeted treatment for people with idiopathic IC-MPGN. The ...